Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Sell
50
PRAX Quote, Financials, Valuation and Earnings
Last price:
$43.16
Seasonality move
:
45.53%
Day range:
$43.03 - $44.76
52-week range:
$26.70 - $91.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
100.86x
P/B ratio:
2.03x
Volume:
147.5K
Avg. volume:
318.1K
1-year change:
12.42%
Market cap:
$892.4M
Revenue:
$8.6M
EPS (TTM):
-$10.72
Analysts' Opinion
-
Consensus RatingPraxis Precision Medicines has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $97.67, Praxis Precision Medicines has an estimated upside of 122.93% from its current price of $43.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing 100% downside risk from its current price of $43.81.
Fair Value
-
According to the consensus of 9 analysts, Praxis Precision Medicines has 122.93% upside to fair value with a price target of $97.67 per share.
PRAX vs. S&P 500
-
Over the past 5 trading days, Praxis Precision Medicines has underperformed the S&P 500 by -1.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Praxis Precision Medicines does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Praxis Precision Medicines has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Praxis Precision Medicines reported revenues of $7.5M.
Earnings Growth
-
Praxis Precision Medicines has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Praxis Precision Medicines reported earnings per share of -$3.29.
Enterprise value:
564.4M
EV / Invested capital:
--
Price / LTM sales:
100.86x
EV / EBIT:
--
EV / Revenue:
65.99x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-54.45%
Net Income Margin (TTM):
-2137.48%
Return On Equity:
-59.11%
Return On Invested Capital:
-59.11%
Operating Margin:
-856.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $2.2M | -- | $431K | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$184.2M | -$130.2M | -$233M | -$41.9M | -$74.7M | |
| EBITDA | -$183.8M | -$129.7M | -$232.7M | -$41.8M | -$74.7M | |
| Diluted EPS | -$57.83 | -$14.90 | -$10.72 | -$2.84 | -$3.29 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $278.6M | $234.5M | $94.4M | $211.8M | $333.6M | |
| Total Assets | $279.3M | $239.5M | $98.4M | $250.4M | $478.7M | |
| Current Liabilities | $13.7M | $45.2M | $29.9M | $18.8M | $39.5M | |
| Total Liabilities | $13.7M | $48.5M | $33.9M | $20.7M | $39.5M | |
| Total Equity | $265.5M | $191M | $64.5M | $229.7M | $439.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$163.8M | -$99.1M | -$163.9M | -$20.9M | -$53M | |
| Cash From Investing | $139.4M | -$86.3M | -$208.3M | -$91.2M | -$51.1M | |
| Cash From Financing | $27.3M | $256.6M | $385.8M | $182.8M | $54.3M | |
| Free Cash Flow | -$163.8M | -$99.1M | -$163.9M | -$20.9M | -$53M | |
PRAX
Sector
Market Cap
$892.4M
$32.6M
Price % of 52-Week High
47.71%
47.07%
Dividend Yield
0%
0%
Shareholder Yield
-34.25%
-0.74%
1-Year Price Total Return
12.42%
-37.62%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$44.36
200-day SMA
Sell
Level
$58.40
Bollinger Bands (100)
Sell
Level
29.14 - 66.26
Chaikin Money Flow
Buy
Level
5.9M
20-day SMA
Buy
Level
$40.90
Relative Strength Index (RSI14)
Buy
Level
61.35
ADX Line
Buy
Level
22.21
Williams %R
Neutral
Level
-26.6212
50-day SMA
Buy
Level
$37.36
MACD (12, 26)
Buy
Level
1.94
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
20M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (20.9512)
Sell
CA Score
(Annual)
Level (-1.7685)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.5497)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Stock Forecast FAQ
In the current month, PRAX has received 8 Buy ratings 0 Hold ratings, and 1 Sell ratings. The PRAX average analyst price target in the past 3 months is $97.67.
-
Where Will Praxis Precision Medicines Stock Be In 1 Year?
According to analysts, the consensus estimate is that Praxis Precision Medicines share price will rise to $97.67 per share over the next 12 months.
-
What Do Analysts Say About Praxis Precision Medicines?
Analysts are divided on their view about Praxis Precision Medicines share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Praxis Precision Medicines is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is Praxis Precision Medicines's Price Target?
The price target for Praxis Precision Medicines over the next 1-year time period is forecast to be $97.67 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PRAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Praxis Precision Medicines is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PRAX?
You can purchase shares of Praxis Precision Medicines via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Praxis Precision Medicines shares.
-
What Is The Praxis Precision Medicines Share Price Today?
Praxis Precision Medicines was last trading at $43.16 per share. This represents the most recent stock quote for Praxis Precision Medicines. Yesterday, Praxis Precision Medicines closed at $43.81 per share.
-
How To Buy Praxis Precision Medicines Stock Online?
In order to purchase Praxis Precision Medicines stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is up 18.98% over the past day.
Buy
59
SYM alert for Jun 17
Symbotic [SYM] is down 1.42% over the past day.
Sell
43
TNXP alert for Jun 17
Tonix Pharmaceuticals Holding [TNXP] is down 5.3% over the past day.
